778 results about "Dexamethasone" patented technology

Drug eluting coating compositions are composed of at least one therapeutic agent dispersed in modified, biologically active binders. The therapeutic agents included in the coating composition are paclitaxel, sirolimus, tacrolimus, everolimus, actinomycin-D, dexamethasone, mycophenolic acid, cyclosporins, estradiol, and derivatives and analogs thereof. These therapeutic agents are applied to the surface of the medical device by a modified, biologically active binders. By using these biologically active binders, the therapeutic agents can be applied to at least one surface of a medical implant without using inert polymer carriers.

The combination of an interleukin-6 (IL-6) antagonist and an antiproliferative drug is described. In its preferred embodiment, the present invention describes the combination of an IL-6 superantagonist, particularly a superantagonist totally incapable of binding gp130 and an antiproliferative drug belonging to the glucocorticoid class (SANT-7 and dexamethasone). The combination according to the present invention has shown surprising synergism in an animal model of multiple myeloma and the ability to overcome the resistance to the antiproliferative drug developed by myeloid cells. The combination according to the present invention is useful for the preparation of a medicament for the treatment of tumours, particularly IL-6-dependent tumours.

The invention relates to a human mesenchymal stem cell culture medium. According to the culture medium, the basal culture medium comprises the following components based on the final concentration: 1-2g/L of human serum albumin, 5-10mg/L of transferring, 2-8mg/L of fibronectin, 1-4mg/L of laminin, 50g/L of Fe(NO3)3.9H2O, 417g/L of FeSO4.7H2O, 1-3mu g/L of estradiol, 2-5mu g/L of testosterone, 1-3mu g/L of progesterone, 39.25-117.74 mu g/L of dexamethasone, 5-10mg/L of insulin, 376.36mg/L of riboflavin, 80.96-242.87mg/L of coenzyme A, 4.41-6.17mg/L of butanediamine, 1-2mg/L of taurine, 0.61-1.85mg/L of aminoethanol, 8.81-26.42mg/L of pyruvic acid, 3.78-7.56mu g/L of sodium selenate, 292.3-584.6mg/L of L-glutamine, 2-8mu g/L of vascular endothelial growth factor, 4-10mu g/L of epidermal growth factor, 4-10mu g/L of basic fibroblast growth factor, 1-5mu g/L of leukaemia inhibitory factor, 1-5mu g/L of insulin-like growth factor-I and 2-8mu g/L of stem cell factor. The culture medium does not contain the animal serum, the potential animal endogenous endotoxin or virus of the animal serum is eliminated, and the culture medium is conveniently applied to clinics.

Methods of modulating uptake of extracellular lysosomal enzymes by administering a pharmaceutical agent and methods of treating a lysosomal storage disease (such as Gaucher disease, Pompe disease, Fabry disease or Niemann-Pick disease) or enhancing enzyme replacement therapy or gene therapy, comprising administering a pharmaceutical agent such as dexamethasone, glucose or insulin, are provided.

A method of propagating mammalian endodermally derived progenitors such as hepatic progenitors, their progeny, or mixtures thereof is developed which includes culturing mammalian progenitors, their progeny, or mixtures thereof on a layer of embryonic mammalian feeder cells in a culture medium. The culture medium can be supplemented with one or more hormones and other growth agents. These hormones and other growth agents can include insulin, dexamethasone, transferrin, nicotinamide, serum albumin, beta-mercaptoethanol, free fatty acid, glutamine, CUSO4, and H2SeO3. The culture medium can also include antibiotics. Importantly, the culture medium does not include serum. The invention includes means of inducing the differentiation of the progenitors to their adult fates such as the differentiation of hepatic progenitor cells to hepatocytes or biliary cells by adding, or excluding epidermal growth factor, respectively. The method of producing mammalian progenitors is useful in that the progenitors can be used subsequently in one or more of the following processes: identification of growth and differentiation factors, toxicological studies, drug development, antimicrobial studies, or the preparation of an extracorporeal organ such as a bioartificial liver.

The invention provides an inducing method and inducing culture medium for differentiation of bone marrow mesenchymal stem cells into osteoblasts in vitro. The inducing culture medium is composed of 1*10<-8> mol/L of dexamethasone, 50 mu mol/L of ascorbic acid and 10 mmol/L of sodium beta-glycerophosphate; and solvent is a supernatant of a sclerite complete culture medium and comprises 10% of fetal calf serum, 100 U/mL of penicillin, 100 mg/L of streptomycin, a mixture of DMEM culture fluid and F12 culture fluid and multiple growth factors secreted by bone cells in the sclerite culture process. According to the invention, bone marrow mesenchymal stem cells of a mouse are purified by replacing the cell culture fluid through an adherent cell passage method, the obtained cells of the first generation are induced, and the supernatant of the sclerite complete culture medium cultured for 72-96 hours is used as the solvent of osteoblast differentiation inducer, thereby obviously improving the in vitro osteogenic differentiation efficiency of bone marrow mesenchymal stem cells.

The invention discloses a medicament formula for relieving pain caused by infusion medicament and preventing phlebitis. The medicament formula can be used for relieving pain caused by intravenous supplementing potassium, infusion mannitol, azithromycin, fructose diphosphate sodium and chemotherapeutic medicaments, and can be used for effectively preventing and treating extravasation phlebitis caused by long-term use of a remaining needle, infusion of vein high-nutrition medicaments, infusion of chemotherapeutic medicaments, infusion extravasation and the like. According to the medicament formula, 20-35ng of anisodamine, 6-13ml of lidocaine, 15-26mg of dexamethasone and 4-6ml of glycerin are arranged in a sterile kidney basin, sterile gauze is coated above a puncture part after being uniformly wetted, and an external preservative film is wound on the gauze. The medicinal formula has the advantages of continually and efficiently relieving local pain caused by infusion medicaments, and effectively preventing and treating local inflammation, swelling pain and stripped cable change caused by infusion.

The invention provides a composition and a method for inducing mesenchymal stem cells to be differentiated to cartilage cells. The composition comprises 20-80 uM of L-ascorbic acid-2-phosphate, 2-10 ng/ml of TGF beta 3, 50-150 nM of dexamethasone, 10-50 ug/ml of vitamin C, 10-50 ug/ml of proline, 0.5-5 ug/ml of indometacin, 1xITS+1premix and 0.5-10 ug/ml of chlormadinone ester. The combination when being used as an inducer of a culture medium can improve differentiation activity and differentiation directionality.

An analgesic composition, is disclosed which comprises a mixture of piroxicam, dexamethasone, ketamine, lidocaine injection, dimethyl sulfoxide, gabapentin and Vanicream™, preferably in the form of a cream or ointment. The composition is applied topically for the relief of pain of arthritis, neuropathy, post-herpetic (shingles) conditions, sore muscles, tendons and ligaments, and local reactions to insect bites or stings.

Genes encoding the transcription factors controlling the core circadian oscillator (BMAL, Clock, NPAS, Per) and their regulatory targets (Rev-erbα, Rev-erb) have been found in adipose tissue. The circadian pattern of these genes was entrained using restricted feeding. The circadian gene expression profiles were examined in mice and in undifferentiated and adipocyte-differentiated human adipose stem cells following exposure to nuclear hormone receptor ligands (dexamethasone or thiazolidinedione) or 30% fetal bovine serum. All three agents induced the initiation of a cyclic expression profile in representative circadian genes in the human adipose stem cells. The circadian genes studied displayed an oscillatory expression profile, characterized by both a zenith and nadir within a 24-28 hr phase. The circadian gene pattern has been lengthened with use of an inhibitor of glycogen synthase kinase 3 beta. Modulation of the circadian pattern to lengthen or shorten can be used to affect weight gain or loss, respectively.

The invention relates to a method for inducing differentiation from mesenchymal stem cells to cartilage cells and application of the mesenchymal stem cells in osteoarthritis, and provides a method for preparing umbilical cord mesenchymal stem cells differentiated to the cartilage cells, mesenchymal stem cells differentiated to the cartilage cells and application of the prepared drug prepared by the mesenchymal stem cells in treatment of the osteoarthritis. The method comprises the following steps of: inducing and culturing the mesenchymal stem cell in a 15ml taper-bottom centrifuge tube by using a globule method; and slightly shaking the centrifuge tube for one time every 24 hours to separate cell sphere from the bottom of the tube, wherein the differentiation inducing culture medium is prepared by adding 100mu g/ml of sodium pyruvate, 10ng/ml TGFbeta3, 100nM of dexamethasone, 25mu g/ml of vitamin C, 40mu g/ml of proline and 1*ITS and 1 of premix into a high-glucose dulbecco modified eagle medium (DMEM). A non-bracket cartilage built by the method can be used for repairing damaged articular cartilages.

Disclosed is a cornea middle term preserving fluid which comprises RPMI 1640 culture liquid, chondroitin sulfate, hyaluronic acid, HEPES cushioning liquid, dexamethasone, low-molecular-weight seaweed polysaccharides, Tobramycin or vancomycin, the preserving fluid has stabilized cell activity during storage period, and higher endothelial cell metabolizing function can be maintained than the US's Opthiol.

The invention provides a kit and method for inducing differentiation from bone mesenchymal stem cells to osteoblasts. The kit comprises an osteoblast inducing culture solution and an osteoblast identification solution, wherein the inducing culture solution comprises a cell culture solution A, a cell culture solution B, a cell culture solution C, a cell culture solution D and a cell culture solution E; the osteoblast identification solution comprises a cell immobilizing solution, coloring agents and a detergent; the cell culture solution A is an alpha-minimum essential medium (MEM) liquid culture medium; the cell culture solution B is fetal bovine serum; the cell culture solution C is a dexamethasone solution; the cell culture solution D is a beta-sodium glycerophosphate solution; the cell culture solution E is a vitamin C solution; the cell immobilizing solution is 4% paraformaldehyde; the coloring agents include sodium thiosulfate, silver nitrate and neutral red; and the detergent is double distilled water.

The invention discloses a method for producing an important steroid hormone dexamethasone methyl tetraenes (5ST) intermediate, which comprises the following steps of: dissolving a methyl dehydrate into an organic solvent, adding a reducing agent into the solution at the temperature of between 5 DEG C below zero and 20 DEG C, and performing one-step reaction to obtain methyl tetraenes with less than 0.8 percent of single impurity, wherein the reducing agent is a mixed reducing agent of 1 to 15 weight parts of chromium trichloride and 0.2 to 8 weight parts of zinc powder. The method for producing the 5ST shortens the reduction reaction into one-step reaction from three-step reaction so as to save the reaction time and facilitate the operation. The method reduces the consumption of chemical raw materials and dangerous goods, reduces the environmental pollution, and reflects the environment-friendly idea of green chemistry.

The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, Avastin®, an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.

The invention provides an induced culture method of liver cells, particularly provides a method for directional induced differentiation of human umbilical cord mesenchymal stem cells into liver cells and more particularly relates to a method for staged directional induced differentiation of human umbilical cord mesenchymal stem cells into liver cells by extracting human umbilical cord mesenchymal stem cells from abandoned umbilical cords through a cell climbing sheet technique, culturing the extracted stem cells, and adding an epidermal growth factor, dexamethasone, a liver cell growth factor, oncostatin and the like.